PRE-LAUNCH PROFESSIONAL AND PATIENT EDUCATION
Nobelpharma America’s first major drug launch, HYFTOR, for the treatment of Facial Angiofibroma Associated with Tuberous Sclerosis Complex (TSC) was preceded by a multi-channel professional education campaign. The primary focus was the campaign was to educate physicians and stakeholders about the symptoms and potential new treatment. A patient education website, faceforwardwithtsc.com was launched in 2023 with the goal of empowering patients and caregivers with resources and a site finder for a Center of Excellence near them.
Patient education and advocacy site
Professional motion graphic and MOA animation
Series of HCP education one-sheets